What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?
about
Crystal structure of HIV-1 Tat complexed with human P-TEFbThe cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disordersThe macrophage: a therapeutic target in HIV-1 infectionCortical consequences of HIV-1 Tat exposure in rats are enhanced by chronic cocaineCrystal structure of HIV-1 Tat complexed with human P-TEFb and AFF4The Startling Properties of Fibroblast Growth Factor 2: How to Exit Mammalian Cells without a Signal Peptide at HandTherapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTNeonatal intrahippocampal HIV-1 protein Tat(1-86) injection: neurobehavioral alterations in the absence of increased inflammatory cytokine activation.HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells.Repeated cocaine treatment enhances HIV-1 Tat-induced cortical excitability via over-activation of L-type calcium channels.Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins.The ins and outs of HIV-1 Tat.A Cyclin T1 point mutation that abolishes positive transcription elongation factor (P-TEFb) binding to Hexim1 and HIV tatNovel biopanning strategy to identify epitopes associated with vaccine protection.Characterization of Tat antibody responses in Chinese individuals infected with HIV-1.Viral-host interactions that control HIV-1 transcriptional elongationTat-induced histopathological alterations mediate hippocampus-associated behavioural impairments in rats.Molecular characterization of full-length Tat in HIV-1 subtypes B and CDidehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic miceA monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-cladeGenetic characterization of HIV type 1 Tat exon 1 from a southern Indian clinical cohort: identification of unique epidemiological signature residues.tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection.HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomesDevelopment of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 LatencyViral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system.Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors.Targeting HIV transcription: the quest for a functional cure.Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.HIV, Tat and dopamine transmission.A structural perspective of RNA recognition by intrinsically disordered proteins.Sequence evolution and escape from specific immune pressure of an HIV-1 Rev epitope with extensive sequence similarity to human nucleolar protein 6.HIV Tat protein: Is Tat-C much trickier than Tat-B?Identification of a highly conserved surface on Tat variants.HIV-Tat Protein Forms Phosphoinositide-dependent Membrane Pores Implicated in Unconventional Protein SecretionHIV vaccine: it may take two to tango, but no party time yet.HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear.Superior HIV-1 TAR Binders with Conformationally Constrained R52 Arginine Mimics in the Tat(48-57) Peptide.
P2860
Q24634569-12A9F3FC-1B3F-42F7-9CBB-4513277D6070Q26777952-2C8344E9-4069-4416-9A2E-59BFB43CFF7DQ26823236-1C5A59E1-B04E-4E27-8B05-9140A8474629Q27013928-ED80A2DF-5B68-4C70-B112-E3920FC5D7FDQ27683254-E41192DF-44C6-407C-965E-1A11A32A9F24Q28085435-3645E5CB-DAC5-4D15-A2D5-A1ACF3BBE4EAQ28476094-EC3A7640-8AFA-456C-858E-E8F404C6951BQ30399828-EAF35C1A-9C37-420C-80AB-8AA0B7F3A232Q33581852-441F7564-31B4-428C-86C1-9DFF725CFA0AQ33605370-7C02BCFF-090F-446A-8150-B6B44DBF07F8Q33897742-B20DDB29-F193-4515-9A0D-1367538F692FQ34219706-1FA99F29-0AE2-4485-ACAD-107226BC2783Q34486331-90B91D48-611A-4FDD-A1E8-A842A5C5392BQ34579037-24E513B7-7C47-4B27-ABB0-50EBE5C80199Q34658608-6C7B7EE6-B128-4B03-B3D3-BA9470175297Q35026881-2B2EC51D-A567-48AD-85A9-949F4439B08CQ35097305-48894BDF-4398-4363-8C02-9C0ED31AD341Q35483696-48D8824C-4832-4946-8BD3-C567E994CC1AQ35559749-BC6B37C4-F84F-450D-8268-7F3F0427C1E3Q35874415-04A4D863-BE8C-4AC4-812B-812EE8270B36Q36177574-FCD9F37B-EB75-4D07-BB65-4A8997187653Q36827396-6BD41CDE-88C2-41FC-B3CA-C266D3036777Q36944251-5A9A5F08-B073-4351-8A57-1DA017A7D492Q37419972-D6584758-129F-4AED-94C0-B8C23294AF64Q37800635-9BA1EB3F-B267-4343-97B1-E03246371157Q38212101-7E1D5860-0D28-4AC6-9307-C33B52ADE70FQ38366762-EB73F98A-D0B0-441B-8A17-8A159E20FAB9Q38533881-216D5E26-A348-4CB8-BC6C-49D998458756Q38812005-CEAC0E7B-1ACB-43A4-B74F-2E55BC760B12Q38845141-0A94EF6D-4A66-470A-B78C-5651AE8F1988Q39400969-B4EFFCA1-0EE9-495B-85C6-2017014F2487Q41329286-4ADC0732-41EA-401B-9C7C-791CA977AC47Q41468434-E36137E6-F405-4642-AC04-203C7474D704Q41578290-34403293-9D6C-4D8B-9E00-FF19918F8B52Q42590256-FE12B71A-3B42-417C-83A8-5FC06FDED90DQ42767857-15B973A5-548B-44DC-8407-83395AD6BB97Q48285475-1F4365F0-7F30-43EC-A79F-0AF2A2D169A7
P2860
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
What does the structure-functi ...... ut developing an AIDS vaccine?
@en
What does the structure-functi ...... ut developing an AIDS vaccine?
@nl
type
label
What does the structure-functi ...... ut developing an AIDS vaccine?
@en
What does the structure-functi ...... ut developing an AIDS vaccine?
@nl
prefLabel
What does the structure-functi ...... ut developing an AIDS vaccine?
@en
What does the structure-functi ...... ut developing an AIDS vaccine?
@nl
P2860
P921
P356
P1433
P1476
What does the structure-functi ...... ut developing an AIDS vaccine?
@en
P2093
Erwann P Loret
Grant R Campbell
P2860
P2888
P356
10.1186/1742-4690-6-50
P577
2009-05-25T00:00:00Z
P5875
P6179
1016433885